Supplied as the monohydrate sulfate salt of the tropane alkaloid racemic hyoscyamine, the product is identified by CAS 5908-99-6 and C₃₄H₄₈N₂O₁₀S·H₂O, with a relative molecular mass of 694.84 g·mol⁻¹. No proprietary model number is assigned in the compendial monograph; the product is identified by chemical name, CAS registry number, and pharmacopoeial name. The material is released as a white or almost white crystalline powder or colourless crystals and is controlled to the USP Atropine Sulfate monograph and the Ph. Eur. monograph for atropine sulfate. The designation “veterinary grade API for tablets, injections, capsules, powders, granules, premix, solutions and eye ointment incorporation” indicates that the active substance is supplied with documentation suitable for veterinary medicinal product manufacture under EU GMP Part II; it is not a finished dosage form. The sulfate salt is selected over the free base for aqueous processing because of its high water solubility, which is a process advantage for injection and ophthalmic solution manufacture but a migration risk in wet-granulated solids.

Pharmacologically, atropine sulfate acts as a competitive antagonist at muscarinic acetylcholine receptors. In veterinary formulations, the dosage forms prepared from this API are used for pre-anaesthetic reduction of salivation and bronchial secretions, management of sinus bradycardia, cycloplegic and mydriatic ophthalmic procedures, and as adjunct therapy in organophosphate toxicity. The API itself is not dispensed directly; the final dose is expressed as atropine sulfate or atropine base equivalent and is species-specific.

Which compendial release parameters govern the API before formulation?

The raw drug substance is tested against identity, assay, pH, loss on drying, residue on ignition, related substances, residual solvents, and elemental impurities. The parameters in the following table are routinely reported by the manufacturer; batch-specific values are stated on the certificate of analysis.

Batch certificates report the actual water content, residual solvents, and assay value. The monohydrate water of crystallisation is 2.59% by mass; overdrying at high temperature can partially convert the material to the anhydrous salt and alter weight-based dispensing. If the solid is to be used in an ophthalmic ointment, the particle size specification in the table is applied; tablet and capsule grades may be ordered with relaxed particle size ranges when the manufacturer has demonstrated equivalent content uniformity.

For ophthalmic ointment manufacture, the micronized API is dispersed into a sterile petrolatum/lanolin base at a base temperature below 60°C; the molten-base temperature is held below the decomposition threshold because atropine sulfate melts with decomposition near 190°C. Particles above 50 µm are controlled by laser diffraction under Ph. Eur. 2.9.31 or USP <429> because larger particles can cause corneal abrasion. A vacuum planetary mixer is used to remove air entrainment, and the finished ointment is tested for sterility under USP <71> or Ph. Eur. 2.6.1 and, for multi-dose containers, preservative effectiveness under USP <51> or Ph. Eur. 5.1.3. If the final ointment is not terminally sterilised, the API is introduced through a validated aseptic process.

When the API is incorporated into injectable formulations, pH and thermal stability limits dominate the manufacturing control strategy

Atropine sulfate injection solutions are compounded in Water for Injection and adjusted with dilute sulfuric acid or sodium hydroxide to a pH within the monograph range of 3.0–6.5 for Atropine Sulfate Injection USP. Hydrolysis of the tropane ester is pH-dependent; free base liberated above pH 7 is poorly soluble and may precipitate. Terminal sterilisation at 121°C for 15 min is acceptable only when the solution is protected from light and the pH is maintained in the acidic region; otherwise degradation to tropic acid and tropine increases. The solution is filtered through a 0.22 µm membrane and filled into amber Type I glass vials or ampoules. Sterility testing follows USP <71> or Ph. Eur. 2.6.1, and bacterial endotoxin limits follow USP <85> or Ph. Eur. 2.6.14. The sulfate salt is preferentially used over atropine base for injection because the base has insufficient aqueous solubility at practical fill volumes.

For tablet and capsule manufacture, the API is routinely pre-blended at a 1:10 ratio with lactose monohydrate or microcrystalline cellulose before final mixing; the active pharmaceutical ingredient concentration in the finished tablet can be below 0.1% w/w in veterinary dosage forms, making segregation and content uniformity the main process risks. Direct compression is preferred over wet granulation because the water-soluble sulfate salt migrates to the granule surface during tray drying. If wet granulation is unavoidable, a fluid-bed granulator with inlet air temperature below 60°C and final granule moisture below 2.0% w/w is used; the dryer filter bag is monitored for electrostatic adhesion of fine drug particles. Content uniformity testing follows USP <905> or Ph. Eur. 2.9.40. Capsule filling on a dosator machine may require the addition of 0.5–1.0% colloidal silicon dioxide to improve flow because the milled API has a high surface area.

For powder blends intended for feed premix, the API is first triturated 1:100 with spray-dried lactose or dextrose using a low-shear mixer; the trituration is then added to the main feed carrier in a ribbon blender at 50–70% nominal fill. Sampling points are taken from the ribbon blender discharge and from the final packaging line; homogeneity is assessed against USP <905> uniformity criteria adapted for bulk powders. The assay method is high-performance liquid chromatography with a limit of quantification below 0.1 µg/mL; if a less sensitive method is used, the trituration ratio must be increased to bring the sample concentration into the validated range. Published data for this specific veterinary configuration is limited; therefore the mixing validation protocol is product-specific and requires replicate batches.

Salt Form, Chirality, and Species-Specific Labeling Differences Against Atropine Base and Hyoscyamine Sulfate

Atropine sulfate is the fully racemic sulfate salt of hyoscyamine; the solid contains equal parts d- and l-hyoscyamine. Hyoscyamine sulfate is the isolated levorotatory enantiomer and is reported to have approximately twice the antimuscarinic receptor binding per unit mass in standard isolated organ assays. This distinction is not cosmetic in veterinary compounding: when hyoscyamine sulfate is substituted for atropine sulfate on a weight-for-weight basis, the dose must be corrected according to the enantiomeric potency difference. Atropine base is a neutral tertiary alkaloid that is sparingly soluble in water and is therefore reserved for non-aqueous formulations or chemical synthesis; the sulfate salt is selected for aqueous ophthalmic and injectable preparations. The sulfate salt also differs in handling behaviour: it is a crystalline monohydrate with a defined water of crystallisation, whereas the base has a lower melting point and a higher risk of thermal degradation during hot-melt processing.

For food-producing species, the veterinary API documentation may require withdrawal-period data and residue depletion studies under regional marketing authorisations; the chemical and compendial quality of the active substance does not differ from the human-grade active substance unless a regional veterinary monograph specifies an additional impurity limit. The term veterinary grade therefore refers to supply-chain documentation, regulatory starting material status, and sometimes particle size or sterile grade options rather than a lower assay limit.

The sulfate salt is incompatible with strong alkalis because free atropine base precipitates; it is also incompatible with strong oxidising agents. In aqueous solution, the rate of hydrolysis increases above pH 6.0 and at temperatures above 60°C; therefore long holding times in heated mixers or autoclaves outside the specified pH window are avoided. The product should not be co-milled with amine-functional excipients or stored in contact with unlined steel if acidic moisture can form. The API is filled into double polyethylene liners inside a fibre drum; the label carries the statement “For veterinary use only” when regional regulation requires it. Storage is at controlled room temperature 20–25°C, protected from light, with excursions permitted between 15°C and 30°C. Hygroscopic uptake above 60% relative humidity may cause caking if the liner is breached. Bulk dispensing is performed under local exhaust ventilation or isolator containment because the active moiety is capable of producing anticholinergic symptoms at low occupational exposure levels.